P R Raghavan, Endocrinol Metab Syndr 2017, 6:5 (Suppl)
DOI: 10.4172/2161-1017-C1-017

P R Raghavan

Nanorx Inc., USA

Treating hypothyroidism and hyperthyroidism with Metadichol ® a novel inverse agonist of VDR

Metadichol® is a nano emulsion of long-chain alcohols found in many foods. It is commonly called Policosanol and is present in foods such as rice, sugar cane, wheat and peanuts. Metadichol® as an inverse agonist on Nuclear Vitamin D receptors (VDR), that are present in cells throughout the body to stimulate the immune system and affects many biological processes to modulate many diseases. 1,25-dihydroxyvitamin D3, the active form of vitamin D, is mainly known for its effects on calcium and phosphate homeostasis with bone, intestine and kidney as principal target tissues. Literature evidence suggests a role for vitamin D in thyroid disease. The ligand for 1,25(OH)2D3, the nuclear vitamin D receptor (VDR), is expressed in many tissues including benign and malignant thyroid tissue. The presentation will show case studies where Metadichol® mitigates, hypothyroidism, hyperthyroidism and also Thyroid Peroxidase Antibody (TPO), most common test for autoimmune thyroid disease; it can be detected in Graves' disease or Hashimoto's thyroiditis and Thyroglobulin antibody (TGAb), this antibody targets thyroglobulin, the storage form of thyroid hormones. Mechanism of action and gene expression studies will be presented.

Biography

P R Raghavan is the CEO of Nanorx Inc., USA. He has completed his PhD in Organic Chemistry from Oregon State University (1979) and an MS in Chemistry (1972) from IIT Mumbai, India. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 15 US and international patents and another 15 pending patent applications.

raghavan@nanorxinc.com

Notes: